Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 10/20 | 0.91 |
| ▸ | CACNA1B | Q00975 | 10/20 | 0.91 |
| ▸ | CACNB1 | Q02641 | 10/20 | 0.91 |
| ▸ | CACNA1C | Q13936 | 7/20 | 0.91 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861078 | 0.95 | CACNA2D1 (1.00) | CACNA2D1CACNA1BCACNB1CACNA1CTDP1 | |
| SCHEMBL2793058 | 0.87 | CACNA2D1 (0.73) | CACNA2D1CACNA1BCACNB1CACNA1CTDP1 | |
| SCHEMBL2796749 | 0.87 | CACNA2D1 (0.73) | CACNA2D1CACNA1BCACNB1CACNA1CTDP1 | |
| SCHEMBL2791111 | 0.86 | CACNA2D1 (0.68) | CACNA2D1CACNA1BCACNB1CACNA1CTDP1 | |
| SCHEMBL2794421 | 0.84 | CACNA2D1 (0.66) | CACNA2D1CACNA1BCACNB1CACNA1CTDP1 | |
| SCHEMBL5017470 | 0.84 | CACNA2D1 (0.77) | CACNA2D1CACNA1BCACNB1CACNA1CTDP1 | |
| SCHEMBL8268615 | 0.84 | CACNA2D1 (0.71) | CACNA2D1CACNA1BCACNB1CACNA1CTDP1 | |
| SCHEMBL2795492 | 0.83 | CACNA2D1 (0.65) | CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL2796512 | 0.82 | CACNA2D1 (0.66) | CACNA2D1CACNA1BCACNB1CACNA1CTDP1 | |
| SCHEMBL2791272 | 0.82 | CACNA2D1 (0.62) | CACNA2D1CACNA1BCACNB1CACNA1CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
| WO-2008031227-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1B, ORAI1 | CACNA2D1 22/4885CACNA1B 2/4885CACNB1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.